ID   WM75
AC   CVCL_7156
SY   WM-75; WM 75; WM75C
DR   BTO; BTO:0003711
DR   cancercelllines; CVCL_7156
DR   Cosmic; 686400
DR   Cosmic; 972272
DR   Cosmic; 1155551
DR   Cosmic; 2163809
DR   ESTDAB; ESTDAB-082
DR   GEO; GSM185200
DR   GEO; GSM185201
DR   GEO; GSM186495
DR   GEO; GSM186496
DR   Progenetix; CVCL_7156
DR   Rockland; WM75-01-0001
DR   Wikidata; Q54994311
RX   PubMed=2068080;
RX   PubMed=2253310;
RX   PubMed=3856042;
RX   PubMed=4053039;
RX   PubMed=15592718;
RX   PubMed=18632627;
RX   PubMed=23851445;
WW   https://www.wistar.org/our-scientists/meenhard-herlyn
CC   Part of: Wistar Institute melanoma cell line collection.
CC   Characteristics: Pigmented.
CC   HLA typing: A*02:01,29:02; B*44:03:01; C*16:01; DPB1*04:01,03:01:01; DQB1*03:02,02:01; DRB1*04:05:01,01:01:01 (PubMed=15592718).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23851445; Wistar).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu88Lys (c.261_262GG>AA) (p.Gly102Lys, c.304_305GG>AA); Zygosity=Unspecified (PubMed=23851445).
CC   Omics: Transcriptome analysis by microarray.
ST   Source(s): ESTDAB; Wistar
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 12
ST   D16S539: 12,13
ST   D21S11: 28,29
ST   D3S1358: 14
ST   D5S818: 11
ST   D7S820: 8,9
ST   FGA: 19,20
ST   TH01: 6
ST   TPOX: 9,11
ST   vWA: 17
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_C277 ! WM373
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 22
//
RX   PubMed=2068080; DOI=10.1073/pnas.88.14.6028;
RA   Cornil I., Theodorescu D., Man S., Herlyn M., Jambrosic J.A.,
RA   Kerbel R.S.;
RT   "Fibroblast cell interactions with human melanoma cells affect tumor
RT   cell growth as a function of tumor progression.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:6028-6032(1991).
//
RX   PubMed=2253310; DOI=10.1007/BF00046337;
RA   Herlyn M.;
RT   "Human melanoma: development and progression.";
RL   Cancer Metastasis Rev. 9:101-112(1990).
//
RX   PubMed=3856042; DOI=10.1093/jnci/74.2.283;
RA   Herlyn M., Balaban G.B., Bennicelli J.L., Guerry D. IV, Halaban R.,
RA   Herlyn D., Elder D.E., Maul G.G., Steplewski Z., Nowell P.C.,
RA   Clark W.H. Jr., Koprowski H.;
RT   "Primary melanoma cells of the vertical growth phase: similarities to
RT   metastatic cells.";
RL   J. Natl. Cancer Inst. 74:283-289(1985).
//
RX   PubMed=4053039;
RA   Herlyn M., Thurin J., Balaban G.B., Bennicelli J.L., Herlyn D.,
RA   Elder D.E., Bondi E., Guerry D. IV, Nowell P.C., Clark W.H. Jr.,
RA   Koprowski H.;
RT   "Characteristics of cultured human melanocytes isolated from different
RT   stages of tumor progression.";
RL   Cancer Res. 45:5670-5676(1985).
//
RX   PubMed=15592718; DOI=10.1007/s00262-004-0561-5;
RA   Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello F., Dodi I.A.,
RA   Lopez Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G.,
RA   Garrido F.;
RT   "High frequency of homozygosity of the HLA region in melanoma cell
RT   lines reveals a pattern compatible with extensive loss of
RT   heterozygosity.";
RL   Cancer Immunol. Immunother. 54:141-148(2005).
//
RX   PubMed=18632627; DOI=10.1158/0008-5472.CAN-08-0235;
RA   Smalley K.S.M., Contractor R., Nguyen T.K., Xiao M., Edwards R.,
RA   Muthusamy V., King A.J., Flaherty K.T., Bosenberg M.W., Herlyn M.,
RA   Nathanson K.L.;
RT   "Identification of a novel subgroup of melanomas with
RT   KIT/cyclin-dependent kinase-4 overexpression.";
RL   Cancer Res. 68:5743-5752(2008).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//